OR4C15

Across TCGA pan-cancer cohorts, OR4C15 Mutation is linked to patient survival in 9 of 34 cancer types, making it the most broadly survival-associated OR4C15 data layer compared with 6 for mass-spec protein.

The strongest signal is observed in rectum adenocarcinoma (READ), where higher OR4C15 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated OR4C15 expression acts as an unfavorable survival marker, although some lineages such as LUSC and SKCM show a favorable association.

READ, PAAD, and SCLC are the cancer types where OR4C15 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
READ	OS	Median	II,III,IV	0.111	0.919	<.001	33	view →
PAAD	DFS	Median	All	0.006	0.505	<.001	15	view →
SCLC	OS	Median	IV	0.137	0.548	.004	12	view →
ESCA	OS	Median	II,III,IV	0.103	0.868	<.001	12	view →
LUAD	DFS	Median	IV	0.342	0.893	<.001	6	view →
LUSC	DFS	Median	All	0.689	0.367	.024	5	view →
SARC	DFS	Median	All	0.109	0.632	.038	3	view →
KIRP	OS	Median	All	0.248	0.705	.049	2	view →
SKCM	OS	Median	All	0.569	0.361	.047	1	view →

Pink = unfavorable, green = favorable. Showing the 9 strongest of 9 lineages.

OR4C15–READ (OS)

Open the READ breakdown →